Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michel Delforge

Showing results (51-60 of 188) with videos related to

Pageof 19
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|July 1, 2023
Predictors of Lenalidomide Refractory Relapse Timing With Newly Diagnosed Multiple Myeloma: A FIRST Trial SubanalysisSalomon Manier, Meletios Dimopoulos, Cyrille Hulin, et al.
JACC. Cardiovascular Imaging|February 22, 2016
The Relation of Ejection Fraction and Global Longitudinal Strain in Amyloidosis: Implications for Differential DiagnosisEfstathios D Pagourelias, Jürgen Duchenne, Oana Mirea, et al.
Future Oncology (London, England)|October 8, 2025
A plain language summary of LocoMMotion - an observational study of treatments used for pretreated multiple myelomaMichel Delforge, Eilidh Duncan, María-Victoria Mateos, et al.
Leukemia & Lymphoma|February 1, 2017
Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myelomaDan T Vogl, Thomas G Martin, Ravi Vij, et al.
Breathe (Sheffield, England)|January 15, 2021
A double-edged swordMartijn Vandebotermet, Frederik Staels, Simone Giovannozzi, et al.
British Journal of Haematology|August 8, 2019
Development and validation of a novel risk stratification algorithm for relapsed multiple myelomaRoman Hájek, Michel Delforge, Marc S Raab, et al.
Leukemia & Lymphoma|October 23, 2013
Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trialMeletios A Dimopoulos, Antonio Palumbo, Roman Hajek, et al.
Cell Research|November 10, 2010
Neutrophil extracellular trap cell death requires both autophagy and superoxide generationQuinten Remijsen, Tom Vanden Berghe, Ellen Wirawan, et al.
Annals of Hematology|February 15, 2011
Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromesMichel Delforge, Dominik Selleslag, Agnès Triffet, et al.
Leukemia & Lymphoma|December 5, 2008
Secondary central nervous system involvement in cyclin D1-negative mantle cell lymphomaDaan Dierickx, Iwona Wlodarska, Vera Vanhentenrijk, et al.
Pageof 19

Showing results (51-60 of 188) with videos related to

Sort By:
Pageof 19
Clinical Lymphoma, Myeloma & Leukemia|July 1, 2023
Predictors of Lenalidomide Refractory Relapse Timing With Newly Diagnosed Multiple Myeloma: A FIRST Trial SubanalysisSalomon Manier, Meletios Dimopoulos, Cyrille Hulin, et al.
JACC. Cardiovascular Imaging|February 22, 2016
The Relation of Ejection Fraction and Global Longitudinal Strain in Amyloidosis: Implications for Differential DiagnosisEfstathios D Pagourelias, Jürgen Duchenne, Oana Mirea, et al.
Future Oncology (London, England)|October 8, 2025
A plain language summary of LocoMMotion - an observational study of treatments used for pretreated multiple myelomaMichel Delforge, Eilidh Duncan, María-Victoria Mateos, et al.
Leukemia & Lymphoma|February 1, 2017
Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myelomaDan T Vogl, Thomas G Martin, Ravi Vij, et al.
Breathe (Sheffield, England)|January 15, 2021
A double-edged swordMartijn Vandebotermet, Frederik Staels, Simone Giovannozzi, et al.
British Journal of Haematology|August 8, 2019
Development and validation of a novel risk stratification algorithm for relapsed multiple myelomaRoman Hájek, Michel Delforge, Marc S Raab, et al.
Leukemia & Lymphoma|October 23, 2013
Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trialMeletios A Dimopoulos, Antonio Palumbo, Roman Hajek, et al.
Cell Research|November 10, 2010
Neutrophil extracellular trap cell death requires both autophagy and superoxide generationQuinten Remijsen, Tom Vanden Berghe, Ellen Wirawan, et al.
Annals of Hematology|February 15, 2011
Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromesMichel Delforge, Dominik Selleslag, Agnès Triffet, et al.
Leukemia & Lymphoma|December 5, 2008
Secondary central nervous system involvement in cyclin D1-negative mantle cell lymphomaDaan Dierickx, Iwona Wlodarska, Vera Vanhentenrijk, et al.
Pageof 19